As Teva leans on tardive dyskinesia med Austedo for growth, the company can feel comfortable that it has a long runway clear from generics—at least from two prominent challengers.
Teva has closed the books on its patent infringement lawsuit against Aurobindo over the Indian company's application to market a generic of Austedo.
Under the agreement, Aurobindo has a license to begin selling its generic in the U.S. in April 2033 or earlier under “certain circumstances."
Austedo is arguably Teva's most important drug. The med pulled in $802 million last year, a 26% increase from 2020.
The Israeli company has managed to hold off another generics player until 2033, as well. Last month, Teva settled with Lupin and agreed to let the latter company sell its generic version of Austedo in April 2033.
Teva filed its complaints against Lupin and Aurobindo last July, claiming infringement against multiple patents it owns.
Austedo is the first and only FDA-approved product for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia, Teva says. The drug scored its original FDA nod back in 2017.
Teva believes that the Aurobindo settlement is a “reflection of the strength of its intellectual property," the company said in a statement.